Triazolam
Halcion (triazolam) is a small molecule pharmaceutical. Triazolam was first approved as Halcion on 1982-11-15. It is used to treat sleep initiation and maintenance disorders in the USA. The pharmaceutical is active against gamma-aminobutyric acid receptor subunit alpha-1, gamma-aminobutyric acid receptor subunit alpha-3, gamma-aminobutyric acid receptor subunit alpha-2, and gamma-aminobutyric acid receptor subunit alpha-5.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Halcion (generic drugs available since 1994-06-01)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Triazolam
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| HALCION | Mylan | N-017892 RX | 1982-11-15 | 2 products, RLD, RS |
Show 1 discontinued
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
109 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pulmonary arterial hypertension | D000081029 | 10 | 9 | 9 | 12 | 6 | 45 | ||
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 3 | 10 | 15 | 6 | 2 | 33 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Interstitial lung diseases | D017563 | EFO_0004244 | J84.89 | — | 6 | 6 | — | 1 | 10 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | 2 | 2 | — | — | 5 |
| Idiopathic pulmonary fibrosis | D054990 | J84.112 | — | 2 | 3 | — | — | 5 | |
| Pulmonary fibrosis | D011658 | J84.10 | — | 3 | 2 | — | 1 | 4 | |
| Ischemia | D007511 | EFO_0000556 | — | 2 | 1 | — | — | 3 | |
| Familial primary pulmonary hypertension | D065627 | I27.0 | — | — | 2 | — | — | 2 | |
| Peripheral vascular diseases | D016491 | EFO_0003875 | I73.9 | — | 1 | 2 | — | — | 2 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | 1 | — | — | 1 |
| Liver transplantation | D016031 | EFO_0010682 | — | 1 | 1 | — | — | 1 | |
| Foot ulcer | D016523 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | 3 | 5 | — | — | — | 6 |
| Healthy volunteers/patients | — | 5 | 1 | — | — | — | 5 | ||
| Reperfusion injury | D015427 | 2 | 2 | — | — | — | 2 | ||
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | — | 1 | — | — | 1 | 2 |
| Delayed graft function | D051799 | 1 | 1 | — | — | — | 1 | ||
| Sarcoidosis | D012507 | EFO_0000690 | D80-D89 | — | 1 | — | — | — | 1 |
| Diabetic foot | D017719 | EFO_1001459 | 1 | 1 | — | — | — | 1 | |
| Calcinosis | D002114 | — | 1 | — | — | — | 1 | ||
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 1 | — | — | — | 1 |
| Persistent fetal circulation syndrome | D010547 | EFO_1001103 | P29.3 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Raynaud disease | D011928 | EFO_1001145 | I73.0 | 1 | — | — | — | — | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TRIAZOLAM |
| INN | triazolam |
| Description | Triazolam is a triazolobenzodiazepine. It has a role as a sedative. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2 |
Identifiers
| PDB | — |
| CAS-ID | 28911-01-5 |
| RxCUI | 10767 |
| ChEMBL ID | CHEMBL646 |
| ChEBI ID | 9674 |
| PubChem CID | 5556 |
| DrugBank | DB00897 |
| UNII ID | 1HM943223R (ChemIDplus, GSRS) |
Target
Agency Approved
GABRA1
GABRA1
GABRA3
GABRA3
GABRA2
GABRA2
GABRA5
GABRA5
Organism
Homo sapiens
Gene name
GABRA1
Gene synonyms
NCBI Gene ID
Protein name
gamma-aminobutyric acid receptor subunit alpha-1
Protein synonyms
GABA(A) receptor subunit alpha-1, GABA(A) receptor, alpha 1, gamma-aminobutyric acid (GABA) A receptor, alpha 1, gamma-aminobutyric acid type A receptor alpha1 subunit
Uniprot ID
Mouse ortholog
Gabra1 (14394)
gamma-aminobutyric acid receptor subunit alpha-1 (P62812)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,262 documents
View more details
Safety
Black-box Warning
Black-box warning for: Halcion, Triazolam
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
62,034 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more